Back to results
US 12,516,116 B2Granted
Homodimeric protein constructs
AssigneeNykode Therapeutics ASA
InventorsPier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
Claims18
A vector comprising a nucleic acid molecule encoding a monomeric protein,
- wherein the monomeric protein forms a homodimeric protein of two identical amino acid chains,
- wherein each amino acid chain comprises:
- a) a targeting unit comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence set forth in positions 5-70 of SEQ ID NO:
- 1;
- b) and an antigenic unit,
- wherein the targeting unit and the antigenic unit are connected through a dimerization motif and
- wherein said homodimeric protein provides MHC class I cross-presentation to CD8+ T cells, and is capable of eliciting an immune response against said antigenic unit.
4 more elements
Dependencies are inferred from the claim text.